Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.30
ALXN's Cash to Debt is ranked lower than
91% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. ALXN: 0.30 )
Ranked among companies with meaningful Cash to Debt only.
ALXN' s Cash to Debt Range Over the Past 10 Years
Min: 0.3  Med: 2.90 Max: No Debt
Current: 0.3
Equity to Asset 0.63
ALXN's Equity to Asset is ranked lower than
57% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ALXN: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
ALXN' s Equity to Asset Range Over the Past 10 Years
Min: 0.04  Med: 0.67 Max: 0.95
Current: 0.63
0.04
0.95
Interest Coverage 8.44
ALXN's Interest Coverage is ranked lower than
83% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 8.44 )
Ranked among companies with meaningful Interest Coverage only.
ALXN' s Interest Coverage Range Over the Past 10 Years
Min: 11.24  Med: 136.04 Max: 292.93
Current: 8.44
11.24
292.93
F-Score: 4
Z-Score: 4.60
M-Score: -2.12
WACC vs ROIC
13.27%
1.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 22.14
ALXN's Operating margin (%) is ranked higher than
87% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. ALXN: 22.14 )
Ranked among companies with meaningful Operating margin (%) only.
ALXN' s Operating margin (%) Range Over the Past 10 Years
Min: -8798.78  Med: 25.18 Max: 38.89
Current: 22.14
-8798.78
38.89
Net-margin (%) 5.37
ALXN's Net-margin (%) is ranked higher than
74% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. ALXN: 5.37 )
Ranked among companies with meaningful Net-margin (%) only.
ALXN' s Net-margin (%) Range Over the Past 10 Years
Min: -8441.21  Med: 17.12 Max: 76.31
Current: 5.37
-8441.21
76.31
ROE (%) 1.98
ALXN's ROE (%) is ranked higher than
76% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. ALXN: 1.98 )
Ranked among companies with meaningful ROE (%) only.
ALXN' s ROE (%) Range Over the Past 10 Years
Min: -136.75  Med: 14.48 Max: 63.11
Current: 1.98
-136.75
63.11
ROA (%) 1.28
ALXN's ROA (%) is ranked higher than
78% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. ALXN: 1.28 )
Ranked among companies with meaningful ROA (%) only.
ALXN' s ROA (%) Range Over the Past 10 Years
Min: -45.22  Med: 9.66 Max: 46.71
Current: 1.28
-45.22
46.71
ROC (Joel Greenblatt) (%) 57.00
ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. ALXN: 57.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALXN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -509.26  Med: 54.85 Max: 173.86
Current: 57
-509.26
173.86
Revenue Growth (3Y)(%) 28.30
ALXN's Revenue Growth (3Y)(%) is ranked higher than
80% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ALXN: 28.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALXN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.5  Med: 38.80 Max: 462.4
Current: 28.3
-68.5
462.4
EBITDA Growth (3Y)(%) 15.20
ALXN's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. ALXN: 15.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALXN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.7  Med: 22.10 Max: 73.2
Current: 15.2
-10.7
73.2
EPS Growth (3Y)(%) -19.50
ALXN's EPS Growth (3Y)(%) is ranked lower than
67% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ALXN: -19.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALXN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.5  Med: 11.05 Max: 76.4
Current: -19.5
-19.5
76.4
» ALXN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

ALXN Guru Trades in Q2 2015

David Swensen 319,273 sh (New)
Andreas Halvorsen 201,756 sh (New)
Mario Gabelli 1,415 sh (New)
Ron Baron 69,764 sh (+69.48%)
Frank Sands 6,519,546 sh (+25.27%)
Lee Ainslie 1,600 sh (+18.52%)
Pioneer Investments 32,062 sh (+0.38%)
Joel Greenblatt Sold Out
Ray Dalio Sold Out
Paul Tudor Jones 1,501 sh (-53.54%)
Jim Simons 13,442 sh (-95.72%)
» More
Q3 2015

ALXN Guru Trades in Q3 2015

Jim Simons 689,542 sh (+5029.76%)
David Carlson 160,000 sh (unchged)
Pioneer Investments 32,062 sh (unchged)
Lee Ainslie Sold Out
Mario Gabelli Sold Out
David Swensen Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
Frank Sands 6,379,857 sh (-2.14%)
Ron Baron 32,624 sh (-53.24%)
» More
Q4 2015

ALXN Guru Trades in Q4 2015

Louis Moore Bacon 30,000 sh (New)
Ron Baron 61,177 sh (+87.52%)
Pioneer Investments 41,785 sh (+30.33%)
David Carlson 160,000 sh (unchged)
Samuel Isaly 223,000 sh (unchged)
Jim Simons Sold Out
Frank Sands 6,056,762 sh (-5.06%)
» More
2016

ALXN Guru Trades in 2016

Spiros Segalas 2,553,911 sh (+7.71%)
Samuel Isaly 223,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Alexion Pharmaceuticals Inc

Baron Funds Comments on Alexion Pharmaceuticals - Feb 08, 2016

We also sold our Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) position in the third quarter to harvest a tax loss. We rebuilt our position this quarter. Alexion is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for Hypophosphatasia (HPP) and Kanuma for Lysosomal Acid Lipase Deficiency (LAL-D), both of which are approved or in the final stages of approval for launch worldwide.



From the Baron Funds Opportunity Fund fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals Inc. - Nov 10, 2015

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for HPP (Hypophosphatasia) and Kanuma for LAL-D (Lysosomal Acid Lipase Deficiency), both of which are approved or in the final stages of approval for launch worldwide. The company recently announced the delay of Strensiq approval by the FDA for manufacturing related issues. With greater uncertainty surrounding the approval of Strensiq, and overall sentiment on the biotech industry souring, we reduced our exposure to the industry and sold our position in Alexion.





From the Baron Opportunity Fund third quarter 2015 letter.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals Inc. - Aug 19, 2015

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a biopharmaceutical company that pioneered the “orphan disease” space by focusing on delivering life-transforming treatments for patients with devastating (life threatening) and ultra-rare (or orphan) diseases. Alexion is a leader in disease education and diagnostic initiatives to ensure that patients for its drugs are rapidly and accurately diagnosed. We believe Alexion’s first commercial drug, known as Soliris, which is used to treat paroxysmal nocturnal hemoglobinuria (called PNH) and atypical hemolytic uremic syndrome (referred to as aHUS), continues to possess a large global growth opportunity. Alexion has a pipeline of additional rare-disease treatments, and recently acquired Synageva, a company with two additional drugs for treating rare and devastating metabolic diseases, as well as a pipeline of other compounds, giving the company what we believe to be the most robust rare disease pipeline in the biotech industry.





From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Alexion Pharmaceuticals Inc

Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
We also sold our Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) position in the third quarter to harvest a tax loss. We rebuilt our position this quarter. Alexion is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for Hypophosphatasia (HPP) and Kanuma for Lysosomal Acid Lipase Deficiency (LAL-D), both of which are approved or in the final stages of approval for launch worldwide. Read more...
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Recent insider sales from company CFOs
According to GuruFocus Insider Data, the recent CFO sales were: Tyson Foods Inc. (NYSE:TSN), Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Gilead Sciences Inc. (NASDAQ:GILD). Read more...
Alexion Pharmaceuticals Loses Position in Swensen's Portfolio Guru sells LendingClub, Antero Resources and Inogen, buys Atara Biotherapeutics and Tesaro
David Swensen (Trades, Portfolio) has been the chief investment officer of Yale University's endowment fund since 1985. He is responsible for managing and investing the university's endowment assets and investment funds. Here are his most weighted stocks that got new positions or lost their positions in the portfolio during the third quarter. Read more...
Baron Funds Comments on Alexion Pharmaceuticals Inc. Guru stock highlight
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for HPP (Hypophosphatasia) and Kanuma for LAL-D (Lysosomal Acid Lipase Deficiency), both of which are approved or in the final stages of approval for launch worldwide. The company recently announced the delay of Strensiq approval by the FDA for manufacturing related issues. With greater uncertainty surrounding the approval of Strensiq, and overall sentiment on the biotech industry souring, we reduced our exposure to the industry and sold our position in Alexion. Read more...
David Swensen Buys Stake in Vanguard MSCI Emerging Markets ETF
In 30 years as chief investment officer at Yale University, David Swensen (Trades, Portfolio) has been quite successful. In the last decade, he has enjoyed an annual return of more than 17.2% on his investments. In his personal investments, Swensen applies knowledge he has gained in that role as well as in his six years on Wall Street prior to taking the job at Yale Read more...
Baron Funds Comments on Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a biopharmaceutical company that pioneered the “orphan disease” space by focusing on delivering life-transforming treatments for patients with devastating (life threatening) and ultra-rare (or orphan) diseases. Alexion is a leader in disease education and diagnostic initiatives to ensure that patients for its drugs are rapidly and accurately diagnosed. We believe Alexion’s first commercial drug, known as Soliris, which is used to treat paroxysmal nocturnal hemoglobinuria (called PNH) and atypical hemolytic uremic syndrome (referred to as aHUS), continues to possess a large global growth opportunity. Alexion has a pipeline of additional rare-disease treatments, and recently acquired Synageva, a company with two additional drugs for treating rare and devastating metabolic diseases, as well as a pipeline of other compounds, giving the company what we believe to be the most robust rare disease pipeline in the biotech industry. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 203.62
ALXN's P/E(ttm) is ranked lower than
92% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. ALXN: 203.62 )
Ranked among companies with meaningful P/E(ttm) only.
ALXN' s P/E(ttm) Range Over the Past 10 Years
Min: 13.92  Med: 77.31 Max: 1113.68
Current: 203.62
13.92
1113.68
Forward P/E 20.08
ALXN's Forward P/E is ranked lower than
53% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. ALXN: 20.08 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 203.62
ALXN's PE(NRI) is ranked lower than
92% of the 242 Companies
in the Global Biotechnology industry.

( Industry Median: 30.06 vs. ALXN: 203.62 )
Ranked among companies with meaningful PE(NRI) only.
ALXN' s PE(NRI) Range Over the Past 10 Years
Min: 13.96  Med: 77.59 Max: 1058
Current: 203.62
13.96
1058
Price/Owner Earnings (ttm) 60.19
ALXN's Price/Owner Earnings (ttm) is ranked lower than
71% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. ALXN: 60.19 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ALXN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 14.17  Med: 55.52 Max: 1108.89
Current: 60.19
14.17
1108.89
P/B 4.09
ALXN's P/B is ranked lower than
56% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. ALXN: 4.09 )
Ranked among companies with meaningful P/B only.
ALXN' s P/B Range Over the Past 10 Years
Min: 3.59  Med: 10.66 Max: 166.91
Current: 4.09
3.59
166.91
P/S 11.83
ALXN's P/S is ranked lower than
52% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. ALXN: 11.83 )
Ranked among companies with meaningful P/S only.
ALXN' s P/S Range Over the Past 10 Years
Min: 9.6  Med: 16.81 Max: 929.17
Current: 11.83
9.6
929.17
PFCF 60.40
ALXN's PFCF is ranked lower than
80% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. ALXN: 60.40 )
Ranked among companies with meaningful PFCF only.
ALXN' s PFCF Range Over the Past 10 Years
Min: 40  Med: 63.10 Max: 3326.67
Current: 60.4
40
3326.67
POCF 38.85
ALXN's POCF is ranked lower than
69% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. ALXN: 38.85 )
Ranked among companies with meaningful POCF only.
ALXN' s POCF Range Over the Past 10 Years
Min: 33.38  Med: 50.07 Max: 83.31
Current: 38.85
33.38
83.31
EV-to-EBIT 58.20
ALXN's EV-to-EBIT is ranked lower than
77% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. ALXN: 58.20 )
Ranked among companies with meaningful EV-to-EBIT only.
ALXN' s EV-to-EBIT Range Over the Past 10 Years
Min: -115.8  Med: 45.80 Max: 499.4
Current: 58.2
-115.8
499.4
EV-to-EBITDA 41.07
ALXN's EV-to-EBITDA is ranked lower than
76% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. ALXN: 41.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALXN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -145  Med: 42.00 Max: 258.3
Current: 41.07
-145
258.3
PEG 5.51
ALXN's PEG is ranked lower than
70% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.25 vs. ALXN: 5.51 )
Ranked among companies with meaningful PEG only.
ALXN' s PEG Range Over the Past 10 Years
Min: 0.68  Med: 1.48 Max: 6.5
Current: 5.51
0.68
6.5
Shiller P/E 164.58
ALXN's Shiller P/E is ranked lower than
88% of the 51 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. ALXN: 164.58 )
Ranked among companies with meaningful Shiller P/E only.
ALXN' s Shiller P/E Range Over the Past 10 Years
Min: 170.93  Med: 375.24 Max: 5207
Current: 164.58
170.93
5207
Current Ratio 3.52
ALXN's Current Ratio is ranked lower than
60% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ALXN: 3.52 )
Ranked among companies with meaningful Current Ratio only.
ALXN' s Current Ratio Range Over the Past 10 Years
Min: 2.3  Med: 7.34 Max: 52.92
Current: 3.52
2.3
52.92
Quick Ratio 3.04
ALXN's Quick Ratio is ranked lower than
61% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ALXN: 3.04 )
Ranked among companies with meaningful Quick Ratio only.
ALXN' s Quick Ratio Range Over the Past 10 Years
Min: 2.03  Med: 7.02 Max: 52.92
Current: 3.04
2.03
52.92
Days Inventory 402.98
ALXN's Days Inventory is ranked lower than
93% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. ALXN: 402.98 )
Ranked among companies with meaningful Days Inventory only.
ALXN' s Days Inventory Range Over the Past 10 Years
Min: 202.61  Med: 292.91 Max: 959.95
Current: 402.98
202.61
959.95
Days Sales Outstanding 79.11
ALXN's Days Sales Outstanding is ranked lower than
59% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. ALXN: 79.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALXN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.74  Med: 106.12 Max: 339.23
Current: 79.11
70.74
339.23
Days Payable 70.31
ALXN's Days Payable is ranked higher than
62% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. ALXN: 70.31 )
Ranked among companies with meaningful Days Payable only.
ALXN' s Days Payable Range Over the Past 10 Years
Min: 44.39  Med: 90.78 Max: 494.52
Current: 70.31
44.39
494.52

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) 1.74
ALXN's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. ALXN: 1.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALXN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 2.00 Max: 3
Current: 1.74
0.2
3
Forward Rate of Return (Yacktman) (%) 36.71
ALXN's Forward Rate of Return (Yacktman) (%) is ranked higher than
89% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 13.93 vs. ALXN: 36.71 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ALXN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -18.5  Med: 0.30 Max: 75.6
Current: 36.71
-18.5
75.6

More Statistics

Revenue(Mil) $2705
EPS $ 0.72
Beta1.62
Short Percentage of Float3.60%
52-Week Range $124.16 - 208.88
Shares Outstanding(Mil)224.02

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 3,086 3,865 4,668
EPS($) 5.10 6.99 8.85
EPS without NRI($) 5.10 6.99 8.85

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:AXP.Germany, ALXN.Switzerland, 0QZM.UK,
Alexion Pharmaceuticals Inc is a Delaware based company, incorporated in 1992. The Company is a biopharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company is also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. It operates in United States, Europe and Asia Pacific. It competes with companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and in other countries and regions, as well as a growing number of large pharmaceutical companies that are developing biotechnology products. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of products and product candidates, including Soliris, are subject to extensive regulation by governmental authorities in the United States, the European Union and other territories.
» More Articles for ALXN

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Alexion Pharmaceuticals Feb 08 2016 
Weekly CFO Sales Highlight: H&R Block, DISH Network, Alexion Pharmaceuticals Jan 03 2016 
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Dec 13 2015 
Weekly Insider Sells Highlights: CDW, Twitter, P&G, Alexion Pharmaceuticals Dec 10 2015 
Alexion Pharmaceuticals Loses Position in Swensen's Portfolio Dec 03 2015 
Jim Simons' Largest Adds of the 3rd Quarter Nov 13 2015 
Baron Funds Comments on Alexion Pharmaceuticals Inc. Nov 10 2015 
Frank Sands Shows Bold Side in Second-Quarter Trades Sep 13 2015 
David Swensen Buys Stake in Vanguard MSCI Emerging Markets ETF Aug 19 2015 
Baron Funds Comments on Alexion Pharmaceuticals Inc. Aug 19 2015 

More From Other Websites
Biotech ETFs Sink on Mixed Q1 Results May 02 2016
Alexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q1, 2016 By the Numbers May 02 2016
Analysts Make Major Changes to Top Biotech Ratings May 01 2016
ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Apr 29 2016
Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALXN-US :... Apr 29 2016
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 28 2016
How Did XBI’s Large Caps Perform? Apr 28 2016
Edited Transcript of ALXN earnings conference call or presentation 28-Apr-16 2:00pm GMT Apr 28 2016
Alexion (ALXN) Lags Q1 Earnings & Revenues, Revises View Apr 28 2016
Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation Apr 28 2016
Sanofi launches $9.3 bln fight for U.S. cancer firm Medivation Apr 28 2016
Sanofi launches $9.3 bln fight for U.S. cancer firm Medivation Apr 28 2016
Alexion (ALXN) Misses on Q1 Earnings and Revenues Apr 28 2016
[$$] Alexion Profit Declines but Revenue Rises Apr 28 2016
Q1 2016 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open Apr 28 2016
Alexion misses Street 1Q forecasts Apr 28 2016
Alexion misses Street 1Q forecasts Apr 28 2016
Alexion Reports First Quarter 2016 Results Apr 28 2016
Alexion Reports First Quarter 2016 Results Apr 28 2016
Alexion (ALXN) Q1 Earnings: What's in Store for the Stock? Apr 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK